Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD4785 · 1 trial · 2 indications
Determined through the evaluation of dose-limiting toxicity (DLT), adverse events, clinical laboratory test results, clinical evaluation and patient reported symptoms
| Arm | Type | Description |
|---|---|---|
| AZD4785 | EXPERIMENTAL | This is a single-arm study in which all patients will receive AZD4785 by IV infusion. Patients will continue to receive treatment with AZD4785 until disease progression, intolerable toxicity, or discontinuation criteria are met. |
| Name | Type | Description |
|---|---|---|
| AZD4785 | DRUG | KRAS Antisense Oligonucleotide |
Inclusion Criteria Part A Dose Escalation: Patients must have histological or cytological confirmation of a solid tumour known to harbour KRAS mutations (e.g., NSCLC, mCRC, pancreatic or cholangiocarcinoma), and have progressed despite standard therapy(ies), or are intolerant to standard therapy(ie...
Top 20 of 84 competitors
AZD4785 is an investigational small molecule being developed for the treatment of Non-Small Cell Lung Cancer. It was studied in patients with advanced solid tumours, including Non-Small Cell Lung Cancer, in a Phase 1 clinical trial. The drug is not approved and remains in clinical development.
AZD4785 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company conducted a Phase 1 clinical trial of AZD4785 in patients with advanced solid tumours.
AZD4785 is in Phase 1 clinical development. A Phase 1 dose-escalation study of AZD4785 in patients with advanced solid tumours has been completed. The drug is investigational and has not been approved by regulatory authorities.
AZD4785 was studied in one clinical trial, identified as NCT03101839, titled 'Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours'. This trial enrolled 28 participants and was conducted in the United States and United Kingdom. The trial has been completed.
No alternative names for AZD4785 have been disclosed. The drug is identified by its code name AZD4785 in clinical trial records and is being developed by AstraZeneca PLC.